Dong-Ying Xie
Overview
Explore the profile of Dong-Ying Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xie D, Wang S, Yang J, Wang L, Chen H, Huai C, et al.
World J Gastroenterol
. 2016 Dec;
22(44):9813-9821.
PMID: 27956805
Aim: To investigate the association between interferon-induced protein with tetratricopeptide repeats 1 () polymorphisms and interferon-α (IFNα) treatment efficiency among Chinese hepatitis B virus (HBV) infection patients. Methods: Two hundred...
12.
Deng H, Wang C, Lai J, Yu S, Xie D, Gao Z
Hepat Mon
. 2016 Nov;
16(9):e40263.
PMID: 27822268
Background: Chronic hepatitis B (CHB) remains a major public health problem worldwide, and the prevalence of CHB patients with hepatic steatosis is gradually increasing. Noninvasive approaches for the assessment of...
13.
Yu S, Deng H, Li X, Huang Y, Xie D, Gao Z
Hepat Mon
. 2016 Apr;
16(1):e34483.
PMID: 27110261
Background: Persistent hepatitis B virus (HBV) infection is sustained by inadequate immune responses, either natural or acquired. Recent studies have suggested that immune responses to viral infection may be affected...
14.
Zheng Y, Xie S, Xie D, Peng L, Lei Z, Deng H, et al.
Hepatol Int
. 2015 Jul;
6(4):727-34.
PMID: 26201522
Purpose: The present study was done to establish an objective, sensitive prognostic scoring system and to determine the applicability of this model in predicting the 3-month mortality of patients with...
15.
Li X, You X, Jie Y, Lin G, Wu Y, Huang M, et al.
Am J Ther
. 2015 Apr;
24(3):e250-e258.
PMID: 25923228
The aim of this study was to evaluate the efficacy and safety of entecavir (ETV) combined treatment with adefovir (ADV) on chronic hepatitic B (CHB) patients who failed to respond...
16.
Hou F, Song L, Yuan Q, Fang L, Ge S, Zhang J, et al.
Theranostics
. 2015 Jan;
5(3):218-26.
PMID: 25553110
A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the...
17.
Mo Z, Li X, Lei Z, Xie D
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
. 2014 May;
31(3):218-20.
PMID: 24812862
Objective: To analyse the clinical features of sparganosis patients and improve cognition in the disease. Methods: The epidemic data, clinical manifestations, auxiliary examinations, diagnosis and treatments of 25 sparganosis patients...
18.
Chen D, Chen Y, Liu J, Xie D, Lu C, Huang Z, et al.
J Clin Virol
. 2013 Dec;
59(1):50-4.
PMID: 24300414
Background/aims: Current international guidelines indicate that finite therapy with nucleos(t)ide analogues (NAs) is possible in chronic hepatitis B (CHB) patients. Here we evaluate the durability of efficacy after telbivudine (LdT)...
19.
Xie C, Li J, Xie D, Lin B, Li M, Gao Z
Zhonghua Yi Xue Za Zhi
. 2013 Nov;
93(27):2167-73.
PMID: 24284254
Objective: To explore the potential value of up-regulator of cell proliferation (URGCP) as a biomarker for predicting the prognosis of hepatocellular carcinoma (HCC). Methods: The expression of URGCP was analyzed...
20.
Zhang G, Xie D, Ye Y, Lin C, Zhang X, Zheng Y, et al.
Liver Int
. 2013 Jul;
34(2):266-73.
PMID: 23890319
Background: Interleukin-6/IL-12 family cytokines play a key role in inflammatory diseases via their effects on the differentiation or regulation of T helper cells. Aims: The aim of this study was...